Enhanced Characterization of Lysine-Linked Antibody Drug Conjugates Enabled by Middle-Down Mass Spectrometry and Higher-Energy Collisional Dissociation-Triggered Electron-Transfer/Higher-Energy Collisional Dissociation and Ultraviolet...

Overview

Journal Antibodies (Basel)

Date 2024 Apr 23

PMID 38651410

Authors

Eleanor Watts

Aarti Bashyal

Sean D Dunham

Christopher M Crittenden

Jennifer S Brodbelt

Affiliations

Soon will be listed here.

Abstract

As the development of new biotherapeutics advances, increasingly sophisticated tandem mass spectrometry methods are needed to characterize the most complex molecules, including antibody drug conjugates (ADCs). Lysine-linked ADCs, such as trastuzumab-emtansine (T-DM1), are among the most heterogeneous biotherapeutics. Here, we implement a workflow that combines limited proteolysis with HCD-triggered EThcD and UVPD mass spectrometry for the characterization of the resulting middle-down large-sized peptides of T-DM1. Fifty-three payload-containing peptides were identified, ranging in mass from 1.8 to 16.9 kDa, and leading to the unambiguous identification of 46 out of 92 possible conjugation sites. In addition, seven peptides were identified containing multiple payloads. The characterization of these types of heterogeneous peptides represents an important step in unraveling the combinatorial nature of lysine-conjugated ADCs.

References

Pandeswari P, Sabareesh V . Middle-down approach: a choice to sequence and characterize proteins/proteomes by mass spectrometry. RSC Adv. 2022; 9(1):313-344. PMC: 9059502. DOI: 10.1039/c8ra07200k. View

Martelet A, Garrigue V, Zhang Z, Genet B, Guttman A . Multi-attribute method based characterization of antibody drug conjugates (ADC) at the intact and subunit levels. J Pharm Biomed Anal. 2021; 201:114094. DOI: 10.1016/j.jpba.2021.114094. View

Sandra K, Vanhoenacker G, Vandenheede I, Steenbeke M, Joseph M, Sandra P . Multiple heart-cutting and comprehensive two-dimensional liquid chromatography hyphenated to mass spectrometry for the characterization of the antibody-drug conjugate ado-trastuzumab emtansine. J Chromatogr B Analyt Technol Biomed Life Sci. 2016; 1032:119-130. DOI: 10.1016/j.jchromb.2016.04.040. View

Fu Z, Li S, Han S, Shi C, Zhang Y . Antibody drug conjugate: the "biological missile" for targeted cancer therapy. Signal Transduct Target Ther. 2022; 7(1):93. PMC: 8941077. DOI: 10.1038/s41392-022-00947-7. View

Huang Y, Mou S, Wang Y, Mu R, Liang M, Rosenbaum A . Characterization of Antibody-Drug Conjugate Pharmacokinetics and in Vivo Biotransformation Using Quantitative Intact LC-HRMS and Surrogate Analyte LC-MRM. Anal Chem. 2021; 93(15):6135-6144. DOI: 10.1021/acs.analchem.0c05376. View

Botzanowski T, Erb S, Hernandez-Alba O, Ehkirch A, Colas O, Wagner-Rousset E . Insights from native mass spectrometry approaches for top- and middle- level characterization of site-specific antibody-drug conjugates. MAbs. 2017; 9(5):801-811. PMC: 5524152. DOI: 10.1080/19420862.2017.1316914. View

Sarrut M, Corgier A, Fekete S, Guillarme D, Lascoux D, Janin-Bussat M . Analysis of antibody-drug conjugates by comprehensive on-line two-dimensional hydrophobic interaction chromatography x reversed phase liquid chromatography hyphenated to high resolution mass spectrometry. I - Optimization of separation conditions. J Chromatogr B Analyt Technol Biomed Life Sci. 2016; 1032:103-111. DOI: 10.1016/j.jchromb.2016.06.048. View

Pacholarz K, Barran P . Use of a charge reducing agent to enable intact mass analysis of cysteine-linked antibody-drug-conjugates by native mass spectrometry. EuPA Open Proteom. 2018; 11:23-27. PMC: 5988552. DOI: 10.1016/j.euprot.2016.02.004. View

Brodbelt J, Morrison L, Santos I . Ultraviolet Photodissociation Mass Spectrometry for Analysis of Biological Molecules. Chem Rev. 2019; 120(7):3328-3380. PMC: 7145764. DOI: 10.1021/acs.chemrev.9b00440. View

10.

Cotham V, Brodbelt J . Characterization of Therapeutic Monoclonal Antibodies at the Subunit-Level using Middle-Down 193 nm Ultraviolet Photodissociation. Anal Chem. 2016; 88(7):4004-13. DOI: 10.1021/acs.analchem.6b00302. View

11.

Cho E, Mayhugh B, Srinivasan J, Sacha G, Nail S, Topp E . Stability of antibody drug conjugate formulations evaluated using solid-state hydrogen-deuterium exchange mass spectrometry. J Pharm Sci. 2021; 110(6):2379-2385. DOI: 10.1016/j.xphs.2021.03.006. View

12.

He J, Su D, Ng C, Liu L, Yu S, Pillow T . High-Resolution Accurate-Mass Mass Spectrometry Enabling In-Depth Characterization of in Vivo Biotransformations for Intact Antibody-Drug Conjugates. Anal Chem. 2017; 89(10):5476-5483. DOI: 10.1021/acs.analchem.7b00408. View

13.

Escobar E, King D, Serrano-Negron J, Alteen M, Vocadlo D, Brodbelt J . Precision Mapping of O-Linked -Acetylglucosamine Sites in Proteins Using Ultraviolet Photodissociation Mass Spectrometry. J Am Chem Soc. 2020; 142(26):11569-11577. PMC: 7394295. DOI: 10.1021/jacs.0c04710. View

14.

Srzentic K, Nagornov K, Fornelli L, Lobas A, Ayoub D, Kozhinov A . Multiplexed Middle-Down Mass Spectrometry as a Method for Revealing Light and Heavy Chain Connectivity in a Monoclonal Antibody. Anal Chem. 2018; 90(21):12527-12535. DOI: 10.1021/acs.analchem.8b02398. View

15.

Beck A, Goetsch L, Dumontet C, Corvaia N . Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017; 16(5):315-337. DOI: 10.1038/nrd.2016.268. View

16.

Desligniere E, Ehkirch A, Duivelshof B, Toftevall H, Sjogren J, Guillarme D . State-of-the-Art Native Mass Spectrometry and Ion Mobility Methods to Monitor Homogeneous Site-Specific Antibody-Drug Conjugates Synthesis. Pharmaceuticals (Basel). 2021; 14(6). PMC: 8225019. DOI: 10.3390/ph14060498. View

17.

Cotham V, Horton A, Lee J, Georgiou G, Brodbelt J . Middle-Down 193-nm Ultraviolet Photodissociation for Unambiguous Antibody Identification and its Implications for Immunoproteomic Analysis. Anal Chem. 2017; 89(12):6498-6504. DOI: 10.1021/acs.analchem.7b00564. View

18.

Watts E, Williams J, Miesbauer L, Bruncko M, Brodbelt J . Comprehensive Middle-Down Mass Spectrometry Characterization of an Antibody-Drug Conjugate by Combined Ion Activation Methods. Anal Chem. 2020; 92(14):9790-9798. DOI: 10.1021/acs.analchem.0c01232. View

19.

Greer S, Sidoli S, Coradin M, Jespersen M, Schwammle V, Jensen O . Extensive Characterization of Heavily Modified Histone Tails by 193 nm Ultraviolet Photodissociation Mass Spectrometry via a Middle-Down Strategy. Anal Chem. 2018; 90(17):10425-10433. PMC: 6383154. DOI: 10.1021/acs.analchem.8b02320. View

20.

Larson E, Roberts D, Melby J, Buck K, Zhu Y, Zhou S . High-Throughput Multi-attribute Analysis of Antibody-Drug Conjugates Enabled by Trapped Ion Mobility Spectrometry and Top-Down Mass Spectrometry. Anal Chem. 2021; 93(29):10013-10021. PMC: 8319120. DOI: 10.1021/acs.analchem.1c00150. View